Mumbai: India`s patent appeals board has revoked a patent granted to GlaxoSmithKline Plc`s breast cancer drug Tykerb, which is a salt form of the original compound, lapatinib.However, the Intellectual Property Appellate Board (IPAB) upheld a patent granted to the original compound, or active pharmaceutical ingredient, citing innovative merit.Fresenius Kabi Oncology, the Indian unit of German healthcare group Fresenius SE, had challenged patents granted for both the original molecule and it`s marketed version Tykerb, saying both molecules lacked innovation.
High voter turnout in 5th phase of Lok Sabha polls
FIR against Misa for disturbing poll process
RCB play hard and party hard too: Mallya
Ananth Kumar calls Congress a non-performer across India